A Phase II Study To Determine The Safety and Efficacy Of The Combination of Vorinostat and Bortezomib In Patients With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 06 Aug 2012
At a glance
- Drugs Bortezomib; Vorinostat
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 08 Jul 2010 Actual patient number (1) added as reported by ClinicalTrials.gov.
- 08 Jul 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 15 Apr 2009 Status changed from not yet recruiting to recruiting as reported by M.D. Anderson Cancer Center.